Financial Lp Hrt Acquires 2,159,052 Shares of Clearmind Medicine (NASDAQ:CMND) Stock

Clearmind Medicine Inc. (NASDAQ:CMND) major shareholder Financial Lp Hrt acquired 2,159,052 shares of the stock in a transaction that occurred on Wednesday, June 10th. The shares were bought at an average cost of $0.15 per share, for a total transaction of $323,857.80. Following the completion of the transaction, the insider directly owned 2,063,266 shares of the company’s stock, valued at $309,489.90. This represents a -2,254.04% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Thursday, June 11th, Financial Lp Hrt sold 225,191 shares of Clearmind Medicine stock. The shares were sold at an average price of $0.12, for a total transaction of $27,022.92.

Clearmind Medicine Price Performance

CMND stock opened at $3.34 on Friday. The company has a market capitalization of $3.41 million, a price-to-earnings ratio of -0.02 and a beta of 0.64. Clearmind Medicine Inc. has a 12 month low of $2.10 and a 12 month high of $524.00. The firm has a 50 day moving average of $6.22 and a two-hundred day moving average of $16.92.

Clearmind Medicine (NASDAQ:CMND) last posted its earnings results on Thursday, March 12th. The company reported ($33.20) EPS for the quarter.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of Clearmind Medicine to a “sell” rating in a research report on Saturday, May 23rd.

Clearmind Medicine Company Profile

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.